Story By Monyonge O’kebati

Kenya is set to strengthen its pharmaceutical manufacturing capacity following a major milestone in plans to establish the country’s first Biopharma Life Sciences Park at Konza Technopolis, in a move aimed at reducing dependence on imported medicines and expanding local production of essential healthcare products.

The proposed project has received financial support from Sweden’s development finance institution, Swedfund International, which will fund preparatory studies to assess the technical and commercial viability of the planned pharmaceutical and life sciences manufacturing hub.

The initiative, spearheaded by Apifa Biotech through a public-private partnership (PPP) with the Technopolis Development Authority (TDA), is expected to position Kenya as a regional centre for pharmaceutical manufacturing, biotechnology innovation and healthcare investment.

The National Treasury approved the project to proceed to the development phase in April 2026, paving the way for further preparations towards its implementation.

According to a joint press release issued on November 12, 2026, a consortium comprising global real estate and investment advisory firm Jones Lang LaSalle (JLL) and healthcare research and analytics company IQVIA has been selected to undertake the feasibility study.

The two firms will bring international expertise in life sciences strategy, infrastructure development, investment advisory and operational planning to guide the proposed development.

Reducing Kenya’s dependence on imported medicines

Technopolis Development Authority Chief Executive Officer John Paul Okwiri said the project represents a significant step towards transforming Konza Technopolis into a destination for pharmaceutical manufacturing and biotechnology investment.

Okwiri noted that the initiative would support Kenya’s ambition to transition from heavy reliance on imported medicines towards greater domestic production.

“The Biopharma Life Sciences Park will position Konza as an emerging centre for life sciences and pharmaceutical manufacturing, helping Kenya move from importing most of its medicines to producing them locally,” said Okwiri.

He further highlighted the importance of public-private partnerships in mobilising the financial resources, technical expertise and private-sector capabilities required to implement large-scale infrastructure projects.

According to Okwiri, collaboration between government agencies and private investors provides a practical approach to translating major development projects into reality.

 Swedfund funding to support project preparation

Swedfund International’s financial commitment will support technical and commercial assessments necessary to establish whether the proposed park is viable and attractive to long-term investors.

Elsa Ekblom, Health Sector Lead, Project Accelerator at Swedfund, said the support would strengthen project preparation and establish a clear pathway towards attracting private investment into Kenya’s pharmaceutical and life sciences industry.

She said the preparatory phase would help maximise the project’s potential national development benefits while creating opportunities for sustainable investment.

The feasibility study is expected to determine the park’s technical requirements, commercial viability, investment structure and implementation roadmap before subsequent development phases.

Apifa Biotech eyes regional pharmaceutical manufacturing hub

Apifa Biotech Board Chairman Dr. Gerald Macharia and Chief Executive Officer Dr. Keter reaffirmed the company’s commitment to advancing the proposed project.

Dr. Keter said the financial support from Swedfund, combined with the expertise of JLL and IQVIA, brings the company closer to realising its ambition of establishing a world-class pharmaceutical and life sciences manufacturing hub in Kenya.

He noted that the proposed facility would serve not only the Kenyan market but also the wider East African Community (EAC) region.

The park, which will be designed, developed and financed by Apifa Biotech, is expected to provide opportunities for collaboration among pharmaceutical manufacturers, researchers, investors and technology enterprises.

The development is also expected to strengthen the relationship between research, technology and industrial production by creating an ecosystem where scientific innovation can translate into commercially viable healthcare solutions.

Supporting Africa’s local pharmaceutical production ambitions

The proposed Biopharma Life Sciences Park aligns with the African Union’s ambition to meet 60 per cent of Africa’s health product needs through local manufacturing by 2040.

It also supports Kenya’s economic development policies targeting local production of at least half of its essential health products.

The project comes amid growing efforts across Africa to strengthen domestic pharmaceutical manufacturing, improve access to essential medicines and reduce vulnerability to disruptions in international supply chains.

By developing local manufacturing capacity, Kenya hopes to improve the availability of medicines and healthcare consumables while creating opportunities for investment and industrial growth.

Konza Technopolis, located approximately 60 kilometres southeast of Nairobi along the Nairobi-Mombasa corridor, is the government’s flagship smart city development.

The establishment of the Biopharma Life Sciences Park would expand Konza’s role beyond technology and digital innovation into pharmaceutical research, biotechnology and industrial manufacturing.

With Swedfund’s financial support secured for the preparatory phase, the next critical step will be the completion of the JLL-IQVIA feasibility study, which will determine the project’s viability and guide its transition towards implementation.